SXTP (60 Degrees Pharma) קצב צמיחת רווח למניה בשנה הנוכחית

The technological potential of 60 Degrees Pharmaceuticals (SXTP) is based on automated pathogen testing, which optimizes laboratory costs. The year-over-year change in earnings per share illustrates the dynamics of this process, where the value 73.00 represents the current metric. Growth is supported by the expansion of the drug Arakoda through B2B contracts with the military-industrial complex, although a critical dependence on a single product creates revenue volatility risks.

This metric calculates the percentage deviation of net income per share relative to the same period last year, measuring the dynamics of bottom-line profitability. This indicator allows for the rapid identification of how logistical disruptions and rising costs impact financial results. For 60 Degrees Pharmaceuticals (SXTP), the absence of sales and increasing R&D expenditures make the volatility of annual earnings per share on GURU.Markets a key marker for the efficiency of pipeline scaling.